Association between potential drug interactions and clinical outcomes in hematopoietic stem cell transplantations

被引:3
作者
Valverde, Ingrid A. P. M. [1 ]
da Silva, Mario J. S. [1 ]
Retto, Maely P. F. [1 ]
机构
[1] Natl Canc Inst Jose Alencar Gomes da Silva, Multiprofess Residency Program, Rio De Janeiro, Brazil
关键词
Hematopoietic stem cell transplantation; pre-transplant conditioning; drug interactions; CYCLOSPORINE;
D O I
10.1177/1078155218775195
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The association of anti-infective, antineoplastic and immunosuppressant drugs makes patients undergoing hematopoietic stem cell transplantation susceptible to the effects resulting from drug interactions. In this study, we analyzed the potential drug interactions in the association between anti-infective, antineoplastic and immunomodulators agents and their clinical effects presented by patients from a bone marrow transplant service of a Brazilian hospital specialized in cancer treatment. The retrospective cohort involved patients in the conditioning phase undergoing transplantation in the year 2013. The chi-square test was used to assess the association and the confidence interval considered was 95%. A total of 53 patients were included in the study and 69.8% (p=0.004) presented some potential drug interaction. Of these, 97.3% (p<0.001) exhibited some symptom that may be associated with these interactions. Interactions with cyclophosphamide and cyclosporine were the most serious effects. There has been a high frequency and variety of interactions that may impair the entire transplant process, putting the patient's life at risk. The potential interactions observed during the conditioning period were associated with the symptoms presented by the patients. Strategies are needed to minimize negative outcomes in transplant patients.
引用
收藏
页码:1105 / 1111
页数:7
相关论文
共 22 条
[11]  
Guastaldi RBF, 2006, THESIS
[12]   Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know [J].
Leather, HL .
BONE MARROW TRANSPLANTATION, 2004, 33 (02) :137-152
[13]  
Makiani MJ, 2017, J RES PHARM PRACT, V6, P61, DOI 10.4103/2279-042X.200992
[14]   Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation [J].
McDonald, GB ;
Slattery, JT ;
Bouvier, ME ;
Ren, S ;
Batchelder, AL ;
Kalhorn, TF ;
Schoch, HG ;
Anasetti, C ;
Gooley, T .
BLOOD, 2003, 101 (05) :2043-2048
[15]  
Nucci M, 2014, Infect Hematol, V27, P49, DOI [10.1007/978-3-662-44000-1_4, DOI 10.1007/978-3-662-44000-1_4]
[16]   Elevation of blood ciclosporin levels by voriconazole leading to leukoencephalopathy [J].
Qu Caihong ;
Liu Weimin ;
Zhu Jieming .
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2013, 4 (04) :294-297
[17]   An overview of infectious complications after allogeneic hematopoietic stem cell transplantation [J].
Sahin, Ugur ;
Toprak, Selami Kocak ;
Atilla, Pinar Ataca ;
Atilla, Erden ;
Demirer, Taner .
JOURNAL OF INFECTION AND CHEMOTHERAPY, 2016, 22 (7-8) :505-514
[18]  
Silva JB, 2014, REV BRAS HEMATOL HEM, V36, P363
[19]   Prevalence and clinical significance of potential drug-drug interaction in hematopoietic stem cell transplantation [J].
Trevisan, Danilo D. ;
Silva, Juliana B. ;
Oliveira, Henrique C. ;
Secoli, Silvia R. ;
Lima, Maria Helena M. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (02) :393-400
[20]  
Vilar S, 2017, BRIEF BIOINFORM OXFO, V10, P1